The stock of 3D Signatures Inc (CVE:DXD) gapped up by $0.11 today and has $1.70 target or 115.00% above today’s $0.79 share price. The 6 months technical chart setup indicates low risk for the $35.51 million company. The gap was reported on Nov, 7 by Barchart.com. If the $1.70 price target is reached, the company will be worth $40.84M more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. About 770,915 shares traded hands or 1099.08% up from the average. 3D Signatures Inc (CVE:DXD) has risen 6.00% since October 8, 2016 and is uptrending. It has outperformed by 4.04% the S&P500.
More notable recent 3D Signatures Inc (CVE:DXD) news were published by: Marketwired.com which released: “3D Signatures Inc. Announces Closing of Qualifying Transaction” on September 09, 2016, also Finance.Yahoo.com with their article: “3D Signatures Inc. Appoints Jason Flowerday as New CEO” published on September 27, 2016, Marketwired.com published: “3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and …” on May 26, 2016. More interesting news about 3D Signatures Inc (CVE:DXD) were released by: Marketwired.com and their article: “3D Signatures Inc. Commences Trading September 13th Under the Symbol (TSX …” published on September 12, 2016 as well as Marketwired.com‘s news article titled: “3D Signatures Inc. and Plicit Capital Corp. Execute Definitive Licencing and …” with publication date: July 21, 2016.
3D Signatures Inc, formerly Plicit Capital Corp, is a Canada personalized medicine firm with a software platform based on the three-dimensional analysis of telomere organization. The company has a market cap of $35.51 million. The Company’s software technology and prognostic methodology targets various diseases that demonstrate genomic instability, including cancer and neurological disorders. It currently has negative earnings. It is engaged in developing over five diagnostic and prognostic products for cancers and neurological disorders, including 3D Telo-PC, 3D Telo-RS, 3D Telo-MM, 3D Telo-BC, 3D Telo-LC and 3D Telo-AD.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.